All News
Half the Experts are Wrong (2.17.2023)
Dr. Jack Cush reviews the news and tries to stump the expert panel this week on the podcast.
Read Article
Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:
Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas, or virtually for RheumNow Live! Will we see you there?
https://t.co/Pv5hywp0ZQ https://t.co/lux83rqNfz
Links:
Dr. John Cush RheumNow ( View Tweet)
Does Methotrexate Increase Skin Cancer Risk?
A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
https://t.co/8AkdkrZs44 https://t.co/ZXrqlbZiZV
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib - Effective in Systemic Lupus Erythematosus
A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE.
https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK
Links:
Dr. John Cush RheumNow ( View Tweet)
Can I stop MTX in RA?
Dr. Janet Pope and Dr. Charis Meng discuss ---should RA Patients with Controlled Disease Taper Methotrexate from Targeted Therapy or Continue It? Risk Differences in Sustaining Remission from a Systematic Review and Meta-analysis.
https://t.co/yMuVVqu0Gf https://t.co/T6PYZ6pJS4
Links:
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Dr Philip Mease, the 2023 recipient of the RWCS "Kahuna" award, for lifetime excellence as a teacher/educator! @RWCSmtg #RWCS23 https://t.co/iXzQsJouu9
Dr. John Cush RheumNow ( View Tweet)
Your #RA patient clearly has active disease that requires new Rx. Is your choice driven by:
Dr. John Cush RheumNow ( View Tweet)
Future therapies for IgG4 re dz. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/3pwBiBTf2N
Dr. John Cush RheumNow ( View Tweet)
“Pathology is helpful but not diagnostic” Dr. Dua #RWCS23 @RheumNow here are your features found on biopsy. https://t.co/J9a6S9XY2D
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Dua reviews IgG4 disease involvement at #RWCS23 @RWCSmtg @RheumNow https://t.co/WHNSxhKGUU
Dr. Rachel Tate uptoTate ( View Tweet)
Steroids assisting options - CTX, LEF or RTX @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/ENfg650B9A
Dr. John Cush RheumNow ( View Tweet)
IgG4 rel dz, steroid response is dramatic, but you need more than steroids for long term remission. @anisha_dua @RWCSmtg @RheumNow https://t.co/wq129L6DXT
Dr. John Cush RheumNow ( View Tweet)
IgG4 levels are often elevated and helpful, but not always. @anisha_dua @RWCSmtg @RheumNow #RWCS23 https://t.co/CcdPcxYIbl
Dr. John Cush RheumNow ( View Tweet)
IgG4 rel dz pathology. @anisha_dua @RWCSmtg @RheumNow https://t.co/LKIZ1BOejK
Dr. John Cush RheumNow ( View Tweet)
IgG4 related disease (a proliferative, fibrotic dz) manifestations by Dr Aisha Dua at RWCS @anisha_dua #rwcs23 @RWCSmtg @RheumNow https://t.co/hy6ZuOY2Ti
Dr. John Cush RheumNow ( View Tweet)
New Laboratory Insights for the ANA+ Consult
A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD).
https://t.co/Ub9pUHPRrV https://t.co/5q2yrNLD5e
Links:
Dr. John Cush RheumNow ( View Tweet)
While his talk didn’t focus on treatment, thoughtfulness regarding treatment for pain is important to our patients. Dr. Mease @RWCSmtg @RheumNow #RWCS23 https://t.co/f946SSeRWo
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Shenoi discusses a new bio markers in sJIA lung disease. #RWCS23 @RheumNow @RWCSmtg https://t.co/Nn3KjmGNfu
Dr. Rachel Tate uptoTate ( View Tweet)
How do you treat sJIA lung disease? Lots of steroids. Lung disease may stabilize but may not resolve. Dr. Shenoi @RWCSmtg #RWCS23 @RheumNow https://t.co/d5HiRy4Ud4
Dr. Rachel Tate uptoTate ( View Tweet)